{"id":52563,"date":"2020-07-24T14:11:00","date_gmt":"2020-07-24T14:11:00","guid":{"rendered":"https:\/\/icrowdnewswire.com\/?p=2670482"},"modified":"2020-07-24T14:11:00","modified_gmt":"2020-07-24T14:11:00","slug":"shareholder-alert-weisslaw-llp-investigates-regeneron-pharmaceuticals-inc","status":"publish","type":"post","link":"https:\/\/ipsnews.net\/business\/2020\/07\/24\/shareholder-alert-weisslaw-llp-investigates-regeneron-pharmaceuticals-inc\/","title":{"rendered":"SHAREHOLDER ALERT: WeissLaw LLP Investigates Regeneron Pharmaceuticals, Inc."},"content":{"rendered":"<p><img loading=\"lazy\" decoding=\"async\" width=\"200\" height=\"122\" src=\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2020\/07\/4000-1-26-7.jpg\" class=\"webfeedsFeaturedVisual wp-post-image\" alt=\"\" style=\"display: block; margin-bottom: 5px; clear:both;max-width: 100%;\" link_thumbnail=\"\" \/><\/p>\n<p>WeissLaw LLP&nbsp;is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Regeneron Pharmaceuticals, Inc.<\/p>\n<p class=\"prntac\"><strong>If you are a Regeneron shareholder and wish to discuss this investigation or have any questions concerning this notice or your rights or interests, visit our website:<\/strong><\/p>\n<p class=\"prntac\"><strong>http:\/\/www.weisslawllp.com\/regeneron-pharmaceuticals-inc\/<\/strong><\/p>\n<p class=\"prntac\"><strong>Or please contact:<\/strong><\/p>\n<p class=\"prntac\"><strong><span class=\"xn-person\">Joshua Rubin, Esq.<\/span><br class=\"dnr\" \/><\/strong>WeissLaw LLP<br class=\"dnr\" \/>1500 Broadway, 16<sup>th<\/sup>&nbsp;Floor<br class=\"dnr\" \/><span class=\"xn-location\">New York<\/span>, NY&nbsp; 10036<br class=\"dnr\" \/><strong>(212)&nbsp;682-3025<br class=\"dnr\" \/><\/strong><strong>(888) 593-4771<br class=\"dnr\" \/>stockinfo@weisslawllp.com<\/strong><\/p>\n<p>The investigation focuses on possible breaches of fiduciary duty and violations of federal securities laws by the Regeneron Board of Directors.&nbsp; Specifically, on&nbsp;<span class=\"xn-chron\">June 24, 2020<\/span>, the U.S. Attorney&#8217;s Office filed a complaint against the Company for alleged violations of the False Claims Act.&nbsp; The complaint alleged that the Company engaged in a sophisticated kickback scheme through which it funneled tens of millions of dollars from a foundation with the goal of covering the co-pay costs of Medicare patients of the Company&#8217;s Eylea drug.&nbsp; According to the U.S. Attorney&#8217;s Office, the scheme undermined the medical system and wasted taxpayers&#8217; monies by causing Medicare to pay out nearly&nbsp;<span class=\"xn-money\">$2 billion<\/span>&nbsp;for access to the drug.<\/p>\n<p>WeissLaw is investigating whether Regeneron&#8217;s Board breached its fiduciary duties to the Company and its shareholders by failing to implement and maintain an effective system of internal controls over its operations.<\/p>\n<p>WeissLaw LLP has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties.&nbsp; We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases.&nbsp; If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at&nbsp;<strong>stockinfo@weisslawllp.com<\/strong><\/p>\n<p class=\"tags\">\n<div><strong>See Campaign: <\/strong><a href=\"http:\/\/http:\/\/www.weisslawllp.com\/regeneron-pharmaceuticals-inc\/\" target=\"_blank\">http:\/\/http:\/\/www.weisslawllp.com\/regeneron-pharmaceuticals-inc\/<\/a><br \/><b>Contact Information:<\/b><br \/>Joshua Rubin, Esq.<br \/>\nWeissLaw LLP<br \/>\n1500 Broadway, 16thFloor<br \/>\nNew York, NY 10036<br \/>\n(212)682-3025<br \/>\n(888) 593-4771<br \/>\nstockinfo@weisslawllp.com<\/p>\n<p><b>Tags:<\/b><br \/><a href=\"\"><\/a>, <a href=\"https:\/\/icrowdnewswire.com\/category\/news-category\/wire\/\" rel=\"category tag\">Wire<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/category\/news-category\/legal-newswire\/\" rel=\"category tag\">Legal Newswire<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/category\/global-regions\/united-states\/\" rel=\"category tag\">United States<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/category\/language\/english\/\" rel=\"category tag\">English<\/a><\/p>\n<p><img loading=\"lazy\" decoding=\"async\" src=\"\" alt=\"image\" width=\"400\" height=\"300\" class=\"cwdfimg\" \/><\/div>\n<div>\n<h3>Contact Information:<\/h3>\n<p>Joshua Rubin, Esq.<br \/>\nWeissLaw LLP<br \/>\n1500 Broadway, 16th\u00a0Floor<br \/>\nNew York, NY\u00a0 10036<br \/>\n(212)\u00a0682-3025<br \/>\n(888) 593-4771<br \/>\nstockinfo@weisslawllp.com<\/p>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p><img loading=\"lazy\" decoding=\"async\" width=\"200\" height=\"122\" src=\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2020\/07\/4000-1-26-7.jpg\" alt=\"\">WeissLaw LLP&nbsp;is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Regeneron Pharmaceuticals, Inc. If you are a Regeneron shareholder and wish to discuss this investigation or have any questions concerning this notice or your rights or interests, visit our website: http:\/\/www.weisslawllp.com\/regeneron-pharmaceuticals-inc\/ Or please contact: Joshua Rubin, &hellip; <a href=\"https:\/\/icrowdnewswire.com\/2020\/07\/24\/shareholder-alert-weisslaw-llp-investigates-regeneron-pharmaceuticals-inc\/\">Continue reading <span>SHAREHOLDER ALERT: WeissLaw LLP Investigates Regeneron Pharmaceuticals, Inc.<\/span><\/a> <a href=\"https:\/\/ipsnews.net\/business\/2020\/07\/24\/shareholder-alert-weisslaw-llp-investigates-regeneron-pharmaceuticals-inc\/\" class=\"more-link\">Continue Reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":46,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3,12,22,54],"tags":[],"class_list":["post-52563","post","type-post","status-publish","format-standard","hentry","category-english","category-legal-newswire","category-united-states","category-wire"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.9 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>SHAREHOLDER ALERT: WeissLaw LLP Investigates Regeneron Pharmaceuticals, Inc. - Business<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ipsnews.net\/business\/2020\/07\/24\/shareholder-alert-weisslaw-llp-investigates-regeneron-pharmaceuticals-inc\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SHAREHOLDER ALERT: WeissLaw LLP Investigates Regeneron Pharmaceuticals, Inc. - Business\" \/>\n<meta property=\"og:description\" content=\"WeissLaw LLP&nbsp;is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Regeneron Pharmaceuticals, Inc. If you are a Regeneron shareholder and wish to discuss this investigation or have any questions concerning this notice or your rights or interests, visit our website: http:\/\/www.weisslawllp.com\/regeneron-pharmaceuticals-inc\/ Or please contact: Joshua Rubin, &hellip; Continue reading SHAREHOLDER ALERT: WeissLaw LLP Investigates Regeneron Pharmaceuticals, Inc. Continue Reading &rarr;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ipsnews.net\/business\/2020\/07\/24\/shareholder-alert-weisslaw-llp-investigates-regeneron-pharmaceuticals-inc\/\" \/>\n<meta property=\"og:site_name\" content=\"Business\" \/>\n<meta property=\"article:published_time\" content=\"2020-07-24T14:11:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2020\/07\/4000-1-26-7.jpg\" \/>\n<meta name=\"author\" content=\"Asiya\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Asiya\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ipsnews.net\/business\/2020\/07\/24\/shareholder-alert-weisslaw-llp-investigates-regeneron-pharmaceuticals-inc\/\",\"url\":\"https:\/\/ipsnews.net\/business\/2020\/07\/24\/shareholder-alert-weisslaw-llp-investigates-regeneron-pharmaceuticals-inc\/\",\"name\":\"SHAREHOLDER ALERT: WeissLaw LLP Investigates Regeneron Pharmaceuticals, Inc. - Business\",\"isPartOf\":{\"@id\":\"https:\/\/ipsnews.net\/business\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ipsnews.net\/business\/2020\/07\/24\/shareholder-alert-weisslaw-llp-investigates-regeneron-pharmaceuticals-inc\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ipsnews.net\/business\/2020\/07\/24\/shareholder-alert-weisslaw-llp-investigates-regeneron-pharmaceuticals-inc\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2020\/07\/4000-1-26-7.jpg\",\"datePublished\":\"2020-07-24T14:11:00+00:00\",\"author\":{\"@id\":\"https:\/\/ipsnews.net\/business\/#\/schema\/person\/3a37b5ed16b9ebaf70290330c45a2e37\"},\"breadcrumb\":{\"@id\":\"https:\/\/ipsnews.net\/business\/2020\/07\/24\/shareholder-alert-weisslaw-llp-investigates-regeneron-pharmaceuticals-inc\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ipsnews.net\/business\/2020\/07\/24\/shareholder-alert-weisslaw-llp-investigates-regeneron-pharmaceuticals-inc\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ipsnews.net\/business\/2020\/07\/24\/shareholder-alert-weisslaw-llp-investigates-regeneron-pharmaceuticals-inc\/#primaryimage\",\"url\":\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2020\/07\/4000-1-26-7.jpg\",\"contentUrl\":\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2020\/07\/4000-1-26-7.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ipsnews.net\/business\/2020\/07\/24\/shareholder-alert-weisslaw-llp-investigates-regeneron-pharmaceuticals-inc\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ipsnews.net\/business\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SHAREHOLDER ALERT: WeissLaw LLP Investigates Regeneron Pharmaceuticals, Inc.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ipsnews.net\/business\/#website\",\"url\":\"https:\/\/ipsnews.net\/business\/\",\"name\":\"Business\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ipsnews.net\/business\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/ipsnews.net\/business\/#\/schema\/person\/3a37b5ed16b9ebaf70290330c45a2e37\",\"name\":\"Asiya\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ipsnews.net\/business\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/d4d7dcc41e3f5a5cad4cf78eca935d2f4c65cc9a91e376789d357e29806bcb91?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/d4d7dcc41e3f5a5cad4cf78eca935d2f4c65cc9a91e376789d357e29806bcb91?s=96&d=mm&r=g\",\"caption\":\"Asiya\"},\"sameAs\":[\"https:\/\/icrowdnewswire.com\/fc\"],\"url\":\"https:\/\/ipsnews.net\/business\/author\/asiya\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"SHAREHOLDER ALERT: WeissLaw LLP Investigates Regeneron Pharmaceuticals, Inc. - Business","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ipsnews.net\/business\/2020\/07\/24\/shareholder-alert-weisslaw-llp-investigates-regeneron-pharmaceuticals-inc\/","og_locale":"en_US","og_type":"article","og_title":"SHAREHOLDER ALERT: WeissLaw LLP Investigates Regeneron Pharmaceuticals, Inc. - Business","og_description":"WeissLaw LLP&nbsp;is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Regeneron Pharmaceuticals, Inc. If you are a Regeneron shareholder and wish to discuss this investigation or have any questions concerning this notice or your rights or interests, visit our website: http:\/\/www.weisslawllp.com\/regeneron-pharmaceuticals-inc\/ Or please contact: Joshua Rubin, &hellip; Continue reading SHAREHOLDER ALERT: WeissLaw LLP Investigates Regeneron Pharmaceuticals, Inc. Continue Reading &rarr;","og_url":"https:\/\/ipsnews.net\/business\/2020\/07\/24\/shareholder-alert-weisslaw-llp-investigates-regeneron-pharmaceuticals-inc\/","og_site_name":"Business","article_published_time":"2020-07-24T14:11:00+00:00","og_image":[{"url":"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2020\/07\/4000-1-26-7.jpg","type":"","width":"","height":""}],"author":"Asiya","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Asiya","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/ipsnews.net\/business\/2020\/07\/24\/shareholder-alert-weisslaw-llp-investigates-regeneron-pharmaceuticals-inc\/","url":"https:\/\/ipsnews.net\/business\/2020\/07\/24\/shareholder-alert-weisslaw-llp-investigates-regeneron-pharmaceuticals-inc\/","name":"SHAREHOLDER ALERT: WeissLaw LLP Investigates Regeneron Pharmaceuticals, Inc. - Business","isPartOf":{"@id":"https:\/\/ipsnews.net\/business\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ipsnews.net\/business\/2020\/07\/24\/shareholder-alert-weisslaw-llp-investigates-regeneron-pharmaceuticals-inc\/#primaryimage"},"image":{"@id":"https:\/\/ipsnews.net\/business\/2020\/07\/24\/shareholder-alert-weisslaw-llp-investigates-regeneron-pharmaceuticals-inc\/#primaryimage"},"thumbnailUrl":"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2020\/07\/4000-1-26-7.jpg","datePublished":"2020-07-24T14:11:00+00:00","author":{"@id":"https:\/\/ipsnews.net\/business\/#\/schema\/person\/3a37b5ed16b9ebaf70290330c45a2e37"},"breadcrumb":{"@id":"https:\/\/ipsnews.net\/business\/2020\/07\/24\/shareholder-alert-weisslaw-llp-investigates-regeneron-pharmaceuticals-inc\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ipsnews.net\/business\/2020\/07\/24\/shareholder-alert-weisslaw-llp-investigates-regeneron-pharmaceuticals-inc\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ipsnews.net\/business\/2020\/07\/24\/shareholder-alert-weisslaw-llp-investigates-regeneron-pharmaceuticals-inc\/#primaryimage","url":"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2020\/07\/4000-1-26-7.jpg","contentUrl":"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2020\/07\/4000-1-26-7.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/ipsnews.net\/business\/2020\/07\/24\/shareholder-alert-weisslaw-llp-investigates-regeneron-pharmaceuticals-inc\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ipsnews.net\/business\/"},{"@type":"ListItem","position":2,"name":"SHAREHOLDER ALERT: WeissLaw LLP Investigates Regeneron Pharmaceuticals, Inc."}]},{"@type":"WebSite","@id":"https:\/\/ipsnews.net\/business\/#website","url":"https:\/\/ipsnews.net\/business\/","name":"Business","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ipsnews.net\/business\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/ipsnews.net\/business\/#\/schema\/person\/3a37b5ed16b9ebaf70290330c45a2e37","name":"Asiya","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ipsnews.net\/business\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/d4d7dcc41e3f5a5cad4cf78eca935d2f4c65cc9a91e376789d357e29806bcb91?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/d4d7dcc41e3f5a5cad4cf78eca935d2f4c65cc9a91e376789d357e29806bcb91?s=96&d=mm&r=g","caption":"Asiya"},"sameAs":["https:\/\/icrowdnewswire.com\/fc"],"url":"https:\/\/ipsnews.net\/business\/author\/asiya\/"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/posts\/52563","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/users\/46"}],"replies":[{"embeddable":true,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/comments?post=52563"}],"version-history":[{"count":0,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/posts\/52563\/revisions"}],"wp:attachment":[{"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/media?parent=52563"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/categories?post=52563"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/tags?post=52563"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}